More on PDI (PDII): Shares are soaring in the post session after posting a Q1 EPS report that...
More on PDI (PDII): Shares are soaring in the post session after posting a Q1 EPS report that blew away Street estimates. Its bottom-line EPS leapt 800% from the same quarter last year, as total sales grew by 36% over the same period. Operating income swung to a profit on the quarter, largely due to cost cutting efforts and the signing of a $17M multi-year sales contract for which PDII will provide a dedicated team to promote a CNS therapeutic product to neurologists and pain specialists. Shares +30% AH.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs